Back Hepatitis C

Hepatitis C

Coverage of 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015)

Hepatitis C treatment for people who inject drugs, including those receiving opioid substitution therapy (OST), was a major theme of the 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015), October 7-9 in Sydney. 

INHSU 2015 Highlights Hepatitis C Prevention and Treatment for People Who Inject Drugs

INHSU 2015: HCV Treatment Works Well for People Who Inject Drugs, but Barriers to Access Remain

INHSU website

10/16/15

alt

INHSU 2015: HCV Treatment Works Well for People Who Inject Drugs, but Barriers to Access Remain

Hepatitis C treatment for people who inject drugs, including those receiving opioid substitution therapy (OST), was a major theme of the 4th International Symposium on Hepatitis Care in Substance Users (INHSU 2015) last week in Sydney. Studies show that treatment using new interferon-free regimens can be highly effective for this population, but barriers including high drug costs and stigma against drug users have hindered widespread access to therapy.

alt

Coverage of 2015 Interscience Conference on Antimicrobial Agents and Chemotherapy

HIVandHepatitis.com coverage of the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, September 17-21, 2015.

Highlights of this year's conference include experimental antiretroviral drugs and treatment strategies, HIV prevention, and comorbidities among people with HIV and HIV/HCV coinfection.

Full listing by topic

ICAAC website

10/6/15

alt

IDWeek 2015: Hepatitis C Mortality Continues to Increase in the U.S.

Deaths related to hepatitis C virus (HCV) continue to rise in the U.S. despite the advent of highly effective interferon-free therapy, according to a CDC study presented yesterday at IDWeek 2015 in San Diego. While death certificate data indicate that hepatitis C is the most common infectious disease cause of death -- exceeding HIV, hepatitis B, and tuberculosis combined -- HCV-related mortality is likely underestimated.

alt

Hepatitis C Cure Associated with Improvement in Liver Fibrosis in People with HIV/HCV Coinfection

A successful response to hepatitis C virus (HCV) therapy is associated with a significant improvement in liver stiffness among people with HIV and HCV coinfection, French investigators report in the September 10 online edition of AIDS.

alt

INHSU 2015 Highlights Hepatitis C Prevention and Treatment for People Who Inject Drugs

An international group of researchers, healthcare providers, advocates, people who use drugs, and people living with hepatitis C are gathering this week in Sydney for the 4th International Symposium on Hepatitis Care in Substance Users, focusing on hepatitis C prevention, care, and treatment for injection drug users. The full program, with links to many of the presentations, is available online. Follow conference news on Twitter #INHSU2015.

alt

Cost of Comprehensive Global Hepatitis Prevention and Treatment Might Peak at $11 Billion in 2025

Reaching the World Health Organization’s (WHO) proposed targets for viral hepatitis control by 2030 could require global funding of US$11 billion per year by 2025, Stefan Wiktor of the WHO Hepatitis Program told the World Hepatitis Summit in Glasgow earlier this month.

alt

People Who Inject Drugs Should Have Access to Hepatitis C Treatment, Expert Panel Recommends

New recommendations on hepatitis C treatment and care encourage physicians to offer treatment to all people who inject drugs who are diagnosed with HCV infection, and to offer a comprehensive package of social support and harm reduction to enable people to adhere to treatment. The recommendations are published this month in the International Journal of Drug Policy, coinciding with the 4th International Symposium on Hepatitis Care in Substance Users taking place this week Sydney, which focuses on the management of hepatitis among drug users.

alt

Achillion's Odalasvir with Sofosbuvir Cured Hepatitis C in 6-8 Weeks in Phase 2 Study

Achillion Pharmaceuticals' experimental NS5A inhibitor odalasvir (ACH-3102) plus Gilead Science's sofosbuvir (Sovaldi), taken without ribavirin, produced sustained virological response at 12 weeks post-treatment in all previously untreated genotype 1 hepatitis C patients treated for 6 or 8 weeks in a small Phase 2 study, according to a recent company announcement. Treatment was safe and well-tolerated.

alt